Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.

  • Johan Farngren
  • Margaretha Persson
  • Bo Ahrén
Publishing year: 2016
Language: English
Pages: 242-249
Publication/Series: Diabetes Care
Volume: 39
Issue: 2
Document type: Journal article
Publisher: American Diabetes Association

Abstract english

Counter-regulatory responses are critical to prevent hypoglycemia in subjects with type 2 diabetes. This is particularly important in insulin-treated patients. This study explored the effect of the glucagon-like peptide 1 receptor agonist lixisenatide on the hormonal counter-regulatory responses to insulin-induced hypoglycemia when added to basal insulin therapy in subjects with type 2 diabetes.


  • Endocrinology and Diabetes


  • Internal Medicine - Epidemiology
  • ISSN: 1935-5548
E-mail: johan [dot] farngren [at] med [dot] lu [dot] se

Research project participant



Research student

Medicine, Lund


Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00